Elicio Therapeutics Inc.

Elicio Therapeutics is a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. The company's proprietary Amphiphile (AMP) platform technology delivers immunotherapeutics directly to the lymph nodes by leveraging albumin protein for targeted delivery, aiming to enhance education, activation, and amplification of cancer-specific T cells. Elicio's lead product candidate, ELI-002 7P, is an off-the-shelf immunotherapy targeting the seven most common KRAS mutations, which drive approximately 25% of all solid tumors. ELI-002 7P was evaluated in the randomized Phase 2 AMPLIFY-7P trial in adjuvant mKRAS-driven pancreatic cancer and is being advanced into a Phase 1 combination study in metastatic pancreatic cancer. The pipeline also includes ELI-007 targeting BRAF-driven cancers and ELI-008 targeting p53 hotspot mutations. The AMP platform was originally developed at the Massachusetts Institute of Technology and has broad potential for cancer immunotherapy applications through internal development, in-licensing, and partnerships. Updated Aug 13, 2026